DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target

Table 2 Univariate and multivariate Cox regression analyses of DLGAP5 expression for overall survival (OS) in TCGA-LUAD cohort

Characteristics	Total (n)	Univariate analysis		Multivariate analysis
Characteristics	Total (n)	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Pathologic T stage	527		< 0.001
T1	176	Reference		Reference
T2	285	1.507 (1.059–2.146)	0.023	1.033 (0.619–1.726)	0.900
T3&T4	66	3.095 (1.967–4.868)	< 0.001	1.681 (0.778–3.635)	0.187
Pathologic N stage	514		< 0.001
N0	345	Reference		Reference
N1	96	2.293 (1.632–3.221)	< 0.001	1.644 (0.740–3.653)	0.222
N2&N3	73	2.993 (2.057–4.354)	< 0.001	2.221 (0.780–6.323)	0.135
Pathologic M stage	381		0.010
M0	356	Reference		Reference
M1	25	2.176 (1.272–3.722)	0.005	1.482 (0.535–4.105)	0.449
Clinical stage	522		< 0.001
Stage I	292	Reference		Reference
Stage II	123	2.341 (1.638–3.346)	< 0.001	0.959 (0.414–2.224)	0.923
Stage III&Stage IV	107	3.635 (2.574–5.132)	< 0.001	1.090 (0.334–3.564)	0.886
Primary therapy outcome	442		< 0.001
CR&PR&SD	371	Reference		Reference
PD	71	3.673 (2.578–5.234)	< 0.001	4.284 (2.730–6.720)	< 0.001
Gender	530		0.570
Female	283	Reference
Male	247	1.087 (0.816–1.448)	0.569
Age	520		0.185
< = 65	257	Reference
> 65	263	1.216 (0.910–1.625)	0.186
Smoker	516		0.777
No	74	Reference
Yes	442	0.942 (0.625–1.420)	0.775
DLGAP5	530		< 0.001
Low	267	Reference		Reference
High	263	1.638 (1.224–2.192)	< 0.001	1.615 (1.065–2.448)	0.024

PD, Progressive Disease; SD, stable disease; PR, partial response; CR, complete response

ISSN: 1479-5876